Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. (Q51366978)
Jump to navigation
Jump to search
scientific article published on 13 November 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. |
scientific article published on 13 November 2011 |
Statements
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. (English)
1 reference
L Thomas
1 reference
R Grempler
1 reference
M Eckhardt
1 reference
F Himmelsbach
1 reference
A Sauer
1 reference
T Klein
1 reference
P Eickelmann
1 reference
M Mark
1 reference
13 November 2011
1 reference
14
1 reference
1
1 reference
94-96
1 reference
1 reference
1 reference